Disclosure profile

Who’s trading PACS?

PACS Group, Inc.

Every disclosed Congress and corporate-insider transaction in PACS (PACS Group, Inc.): 29 trades from 9 politicians and executives, each AI-scored. Updated as new filings land.

Create a free account to open trades, see the full AI breakdown, and get live alerts when PACS is traded.

Create a free account →

FilerActionAmountFiledScore

Jergensen JoshuaSEC Form 4Sell$1.6M2026-07-163

Hancock MarkSEC Form 4Sell$462k2026-07-163

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$150k2026-07-154

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$5.3M2026-07-157

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$464k2026-07-145

Hancock MarkSEC Form 4Sell$913k2026-07-103

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$224k2026-07-094

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$917k2026-07-086

Dilsaver Evelyn SSEC Form 4——2026-07-064

LEAVITT TAYLOR S.SEC Form 4——2026-07-063

Lewis Michelle ReneeSEC Form 4Sell$372k2026-07-064

Hancock MarkSEC Form 4—$6.5M2026-07-064

Millard JacquelineSEC Form 4——2026-07-063

Conway Patrick HughSEC Form 4——2026-07-063

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$6.4M2026-07-065

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$577k2026-07-025

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$274k2026-07-015

Lewis Michelle ReneeSEC Form 4Sell$600k2026-06-263

Hancock MarkSEC Form 4Sell$5.6M2026-06-265

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$5.6M2026-06-256

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy$1.7M2026-06-256

Hancock MarkSEC Form 4Sell—2026-06-225

PACS Group, Inc. (PACS) (CIK 0002001184)SEC Form 144Buy—2026-06-174

Hancock MarkSEC Form 4Sell—2026-06-176

Dilsaver Evelyn SSEC Form 4——2026-06-124

LEAVITT TAYLOR S.SEC Form 4——2026-06-124

Millard JacquelineSEC Form 4——2026-06-125

Conway Patrick HughSEC Form 4——2026-06-124

MITCHELL JOHN TODDSEC Form 4Sell—2026-05-194

Public-record disclosures (SEC Form 4 & Congressional PTRs). Research tool, not investment advice.